Reversible Myelofibrosis Induced by Tuberculosis

Viallard, Jean‐François; Parrens, Marie; Boiron, Jean‐Michel; J, Texier; Mercié, P.; Pellegrin, Jean‐Luc

doi:10.1086/340524

Cited by 24 publications

(18 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myelofibrosis is also described in nonmalignant conditions such as HIV infection, endocrine disorders affecting the bone including Paget's disease, rickets, and primary and secondary hyperparathyroidism [3,4,5,6,7]. Myelofibrosis in the setting of a defined autoimmune disease is termed secondary autoimmune myelofibrosis (AIMF) and is most commonly associated with systemic lupus erythematous (SLE), but has also been reported with systemic sclerosis and Sjögren syndrome [8,9,10,11,12].…”

Section: Introductionmentioning

confidence: 99%

Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome

Piatek¹,

Vergara‐Lluri

Pullarkat

et al. 2017

Acta Haematol

View full text Add to dashboard Cite

Background: Autoimmune myelofibrosis (AIMF) is an underrecognized cause of nonmalignant bone marrow fibrosis which occurs in the presence or absence of a defined systemic autoimmune disease. Patients with AIMF present with cytopenias and autoantibodies, and have a distinctive nonclonal myelofibrosis on bone marrow examination. AIMF is distinguished from primary myelofibrosis by the absence of splenomegaly, eosinophilia, or basophilia, and the absence of abnormal myeloid, erythroid, or megakaryocytic morphology. Objectives: The objective of the study was to describe the clinical presentation and outcomes of patients with AIMF. Methods: We conducted a single-institution, retrospective chart review of patients diagnosed with AIMF to investigate clinical presentations, therapies, and outcomes. Results: Twelve patients with AIMF were identified with a mean follow-up of 5.8 years. All patients had detectable autoantibodies and the majority had concomitant autoimmune disorders. Four patients experienced a complete response of cytopenias and 3 patients experienced a partial response (PR) of cytopenias with immunosuppressive therapy. One patient achieved a PR following splenectomy. No patients were diagnosed with myeloproliferative neoplasms during the follow-up period. Conclusions: AIMF contributes to cytopenias in the subset of patients with various autoimmune disorders. The majority of patients with AIMF experience an improvement in cytopenias with immunosuppressive therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome

Piatek¹,

Vergara‐Lluri

Pullarkat

et al. 2017

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…SMF occurs in a variety of systemic diseases, including tuberculosis, metastatic carcinoma, osteopetrosis and toxic marrow injury following irradiation or chemical exposure (19,20). SMF is also observed in a variety of hematological malignancies, including acute megakaryoblastic leukemia, chronic myeloid leukemia and hairy cell leukemia.…”

Section: Discussionmentioning

confidence: 99%

“…However, small lymph nodes (1-2 cm in diameter) remained in the neck and supraclavicular after 4 courses of chemotherapy. Therefore, the patient was treated with 2 courses of BEACOPP (bleomycin, 15 mg, day 8; etoposide, 200 mg, days 1-3; doxorubicin, 80 mg, day 1; cyclophosphamide, 1,200 mg, day 1; vincristine, 4 mg, day 8; procarbazine, 700 mg, days 1 and 15; and prednisone, 80 mg, days 1-14) combined with local radiotherapy (2 Gy, days [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Residual lesions were not observed on CT scans, and a BM biopsy demonstrated recovery of hematopoiesis and a disappearance of fibrosis.…”

Section: Case Reportmentioning

confidence: 99%

Hodgkin's lymphoma associated with myelofibrosis: A case report

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. In the present study, the case of a patient with nodular sclerosing Hodgkin's lymphoma (NSHL) presenting with diffuse fibrosis of the bone marrow (BM) was reported. A 30-year-old male complained of fever for 1 year, as well as lumbago, lymph node swelling and night sweats for 3 months. A biopsy of the lymph nodes established a diagnosis of NSHL. Aspiration of BM was a dry tap, and the BM biopsy demonstrated marked myelofibrosis with increased proliferation of reticulin fiber. Multiple skeletal lesions were detected in the patient's vertebra, pelvis, sternum and bilateral femur by magnetic resonance imaging and computed tomography. Following numerous courses of chemotherapy and radiotherapy, remission of the lymphoma was achieved. Subsequently, the BM aspiration became possible, and BM biopsy demonstrated a reduction in fibrosis.

show abstract

“…Treatment and prognosis depends on the etiology of myelofibrosis. Treatable causes must be recognized, because addressing the primary disorder, such as infection or autoimmune disease, may improve marrow fibrosis (147, 148, 152). The choice of treatment for primary myelofibrosis is determined in a risk-adaptive manner.…”

Section: Myelophthisic Anemiamentioning

confidence: 99%

Anemia of Central Origin

Ishii

Young

2015

Seminars in Hematology

View full text Add to dashboard Cite

Hypoproliferative anemia results from the inability of bone marrow to produce adequate numbers of red blood cells. The list of conditions that cause hypoproliferative anemia is long, starting from common etiologies as iron deficiency to rarer diagnoses of constitutional bone marrow failure syndromes. There is no perfect diagnostic algorithm, and clinical data may not always clearly distinguish “normal” from “abnormal”, yet it is important for practicing clinicians to recognize each condition so that treatment can be initiated promptly. This review describes diagnostic approaches to hypoproliferative anemia, with particular emphasis on bone marrow failure syndromes.

show abstract

Reversible Myelofibrosis Induced by Tuberculosis

Cited by 24 publications

References 9 publications

Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome

Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome

Hodgkin's lymphoma associated with myelofibrosis: A case report

Anemia of Central Origin

Contact Info

Product

Resources

About